Evérolimus ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 34 | Neurofibromatosis | 1 |
34. Neurofibromatosis
Clinical trials : 137 / Drugs : 213 - (DrugBank : 76) / Drug target genes : 87 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-002228-42-FR (EUCTR) | 29/08/2011 | N/A | N/A - AFINF2 | MedDRA version: 14.0;Level: PT;Classification code 10029268;Term: Neurofibromatosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cancer [C04] | Trade Name: Afinitor Product Name: Afinitor INN or Proposed INN: Evérolimus Other descriptive name: RAD001 | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | NULL | Not Recruiting | Female: yes Male: yes | Phase 2 | France |